Background. Contemporary vancomycin dosing schemes are designed to achieve an area under the curve (AUC) to minimum inhibitory concentration (MIC) ratio of ≥400. However, scant clinical data exist to support this target and available data relied on pharmacokinetic formulas based on daily vancomycin dose and estimated renal function (demographic pharmacokinetic model) to estimate AUCs.
Despite its introduction more than a half-century ago, the optimal dosing strategy for vancomycin remains undefined. Contemporary vancomycin dosing schemes are designed to achieve an area under the curve (AUC) to minimum inhibitory concentration (MIC) ratio ≥400 for serious methicillin-resistant Staphylococcus aureus (MRSA) infections [1, 2] . Although this target is based on the best available evidence [1] [2] [3] [4] [5] [6] , it is largely derived from neutropenic mouse thigh infection model data [3] . The best clinical evidence supporting AUC/ MIC ratio ≥400 is drawn from a retrospective evaluation of patients with S. aureus pneumonia [5] . Two recent studies of patients with MRSA bloodstream infections (BSIs) have also identified similar vancomycin AUC/ MIC ratio targets [7, 8] . Although these evaluations provide further evidence that the vancomycin pharmacodynamic target is an AUC/MIC ratio of at least 400, all evaluations used a simple formula based on daily vancomycin dose and estimated renal function to estimate AUC values [5, 7, 8] . In most cases, they used the Cockcroft-Gault creatinine clearance (CrCl) formula. There is considerable interpatient variability in vancomycin exposure profiles in clinical practice and it is difficult to generate valid estimates of exposure variables in a given individual based on glomerular filtration estimation formulas alone [9] [10] [11] . To date, we are only aware of 2 small-scale vancomycin exposure-response clinical evaluations that considered individualized estimates of the vancomycin AUC based on collected levels and doses received [12, 13] . Thus, there is a critical need for additional, larger-scale clinical studies that utilize individualized estimates of exposure profiles based on measured concentrations.
Although AUC/MIC ratio is the prevailing vancomycin exposure target, AUCs are not determined in clinical practice due to the perceived difficulty in calculating the AUC [2] . Expert guidelines recommend maintaining a minimum ("trough") concentration (C min ) between 15 and 20 mg/L as a surrogate marker for an AUC/MIC ratio ≥400 [1, 2] . However, the clinical benefits of maintaining higher vancomycin trough values have not been well described [14] [15] [16] [17] [18] [19] . The intent of this study was to quantitatively evaluate the relationship between vancomycin exposure variables (ie, C min /MIC, AUC/MIC) and outcomes among patients with MRSA BSIs. Bayesian techniques [20] [21] [22] were used to estimate the vancomycin concentration-time profile for each patient. The Bayesian approach used in this study to estimate exposure profiles has recently been validated as a method to estimate vancomycin exposure values with low bias and high precision in situations where trough-only pharmacokinetic (PK) data are available [22] . As a secondary objective, this study compared the predictive performance of the Bayesian relative to the formulabased approach for estimating exposure profiles.
METHODS

Experimental Design and Study Population
A retrospective cohort study was performed among hospitalized patients with MRSA BSIs treated with vancomycin at Albany Medical Center Hospital between January 2005 and June 2009. Patients meeting the following criteria were included: (1) age ≥18 years; (2) absolute neutrophil count ≥1000 cells/ µL; (3) MRSA culture met the Centers for Disease Control and Prevention criteria for BSI [23] ; (4) index MRSA isolate available for phenotypic characterization; (5) not receiving dialysis; (6) received vancomycin within 48 hours of index culture; (7) received vancomycin for at least 2 days; and (8) had ≥1 vancomycin level collected within the first 5 days of therapy. If a patient had >1 MRSA BSI during the study period, additional episodes were included if they occurred >60 days after completion of antibiotic therapy for the previous BSI. The study was limited to patients who received vancomycin within 48 hours of index culture collection as this has been identified as the critical time window for delivery of appropriate antibiotics for patients with MRSA BSIs [24] . The study was approved by expedited review by the institutional review board of Albany Medical Center Hospital, and a HIPAA waiver was obtained.
Patient Data
Data elements included demographics, medical history, and comorbidities [18] , recent healthcare institution exposure in the past 6 months, receipt of antibiotics in the 30 days prior to the index culture collection, hospitalization history, and CrCl estimated by the Cockcroft-Gault formula [25] at index culture collection. Illness severity was defined by the Acute Physiology and Chronic Health Evaluation II score (based on the worst physiological score in the 48 hours prior to index culture collection) [26] and the Chronic Disease Score-Infectious Diseases score (determined at admission) [27] . Additional data elements included source of MRSA BSI, mortality risk associated with infection source [24, 28, 29] , presence of infective endocarditis [30] , infection source control intervention, microbiologic data, treatment data, occurrence of nephrotoxicity (defined as either a 50% or 0.5 mg/dL increase in serum creatinine, whichever was greater, from initiation of vancomycin to 48 hours postcompletion among patients with a baseline serum creatinine level <2 mg/dL [2] ), and outcomes.
Microbiologic Data and Phenotypic and Genotypic Characterization
All isolates were identified as S. aureus according to standard methods. Initial susceptibility testing for oxacillin resistance was performed according to Clinical and Laboratory Standards Institute guidelines [11] . Isolates were stored in trypticase soy broth with 20% glycerol at −70°C. All available MRSA BSIs were shipped to JMI Laboratories (North Liberty, Iowa) for determination of broth microdilution (BMD) MIC [31] , Etest MIC (according to the manufacturer's instructions; bioMérieux, Marcy l'Etoile, France), minimum bactericidal concentration (MBC) [32] , heterogeneous vancomycin-intermediate S. aureus (hVISA) [33] , and δ-lysin activity [34] . Details on these testing methodologies are provided in the Supplementary Methods. For patients with multiple MRSA blood cultures, only the index isolate was considered in the analysis.
Treatment Data
All antibiotic treatment and vancomycin concentration data were collected. Vancomycin exposure variables were estimated using ADAPT 5, a "computational modeling platform developed for PK/PD [ pharmacodynamic] applications" [20] . Given the time-critical nature of the first 48 hours of treatment for MRSA BSIs [24] , vancomycin exposure variables were estimated using the maximal a posteriori probability (MAP) procedure in ADAPT 5 for hours 0-24 (day 1) and 24-48 (day 2) [20, 21] . This approach has recently been validated as a way to estimate AUC values with low bias and high precision with trough-only PK sampling [22] .
In brief, the mean parameter vector and covariance matrix from a previously described 2-compartment vancomycin model [35] [36] [37] was embedded in the PRIOR subroutine of ADAPT 5 (Bayesian prior) [20] . The MAP procedure in estimation module (ID) of ADAPT 5 was then used to estimate the revised probability distribution of a given patient's PK parameter values after dosing and drug concentration data were taken into account (Bayesian conditional posterior). With the Bayesian posterior PK information for a given individual, ADAPT 5 was used to estimate the following vancomycin exposure variables based on the dosing schedule received: (1) C min24h , (2) C min48h , (3) AUC 0−24h , and (4) AUC 24−48h . The predictive performance of the Bayesian approach was assessed by comparing the predicted to the observed concentrations. The predictive performance of the Cockcroft-Gault formula-based approach using the mean parameter vector of the PK model [35] [36] [37] used in this study was also determined.
Outcomes
Due to the retrospective nature of the study, an objective assessment of treatment failure that included only readily measurable study endpoints was used [18, 38] . Failure was defined as any of the following: (1) death within 30 days of index MRSA blood culture (30-day mortality), (2) microbiological failure (blood culture growing MRSA obtained 7 days after the initiation of therapy and before therapy completion), or (3) recurrence of MRSA bacteremia within 60 days of discontinuation of therapy [18, 38] . The Social Security Death Index was accessed to determine the vital status of patients discharged within 30 days of MRSA bacteremia onset.
Data Analysis Plan
The primary vancomycin exposure variables considered in the analyses included: (1) C min24h /MIC BMD , (2) C min48h /MIC BMD , (3) AUC 0−24h /MIC BMD , (4) AUC 24−48h /MIC BMD , (5) C min24h / MIC ETEST , (6) C min48h /MIC ETEST , (7) AUC 0−24h /MIC ETEST , and (8) AUC 24−48h /MIC ETEST . Vancomycin exposure variables were modeled as both continuous and dichotomous variables. Bivariate associations between vancomycin exposure variables and outcomes and baseline covariates and outcomes were assessed using Fisher exact test (categorical variables) and Student t test and Mann-Whitney U test (continuous variables). Breakpoints in the distribution of continuous vancomycin exposure variables were sought by Classification and Regression Tree (CART) analysis [39] . We also examined the relationship between C min ≥15 mg/L and outcomes, given the recent expert guidelines recommendations [1, 2] .
Poisson regression analyses with robust variance estimates [40, 41] were performed to quantify the association between each vancomycin exposure variable and failure and 30-day mortality after adjustment for potential confounding variables. Each vancomycin exposure variable was evaluated separately. All potential confounding variables (baseline covariates associated with outcomes at P < .2) were included at model entry and were retained as confounders if the relative risk (RR) of the vancomycin exposure variable changed by >10%. All calculations were computed using SAS software, version 9.3 (SAS Institute, Cary, North Carolina) and CART software (Salford Systems, San Diego, California). 
RESULTS
There were 238 unique episodes of MRSA BSIs during the observation period, and 123 met the inclusion criteria. Reasons for exclusion were (1) no MRSA isolate (n = 18); (2) receipt of dialysis (n = 58); (3) treatment with alternative anti-MRSA antibiotic (n = 20); (4) lack of anti-MRSA antibiotics (n = 10); and (5) no vancomycin measurements (n = 10). Among cases treated with alternative antibiotics, most received either linezolid (n = 11) or daptomycin (n = 5). Distribution of microbiologic phenotypes, exposure variables, and outcomes among the 123 included cases are provided in Table 1 . In situations where source control was warranted, there was an attempt at source control in most cases. Among patients who experienced "failure," there was a documented intervention in the medical record to "control the source" in >95% of cases.
Results of the observed vs predicted plots for the Bayesian and formula-based estimation approaches are shown in Figure 1 . There were 282 available concentrations among the 123 cases. The regression line from the observed-predicted plot for the Bayesian approach was 0.994 × predicted + 0.08, and the R 2 was 0.99 ( Figure 1A) . The regression line for the formulabased approach was 0.54 × predicted + 8.2 and the R 2 was 0.32 ( Figure 1B ). Bivariate comparisons between vancomycin exposure variables and failure are displayed in Figures 2A and 2B . Breakpoints were identified for all continuous vancomycin exposure variables with CART. Cases with C min /MIC BMD values in excess of the CART-derived thresholds had higher incidences of failure, whereas the inverse was observed for the CART-derived C min /MIC ETEST variables (Figure 2A) . Similarly, failure was higher among patients with trough levels ≥15 mg/L relative to those with trough levels <15 mg/L on both day 1 (30.6% vs 50.0%, respectively; P = .2) and day 2 (30.1% vs 40.0%, respectively; P = .3). In contrast, failure was uniformly less pronounced in patients who achieved the AUC/MIC BMD and AUC/MIC ETEST CART-derived thresholds relative to those who did not (Figure 2B) . For all 4 AUC/MIC exposure variables, failure was nearly doubled in patients with exposures below the CART-derived thresholds vs those in excess of the breakpoints. Bivariate comparisons between the CART-derived vancomycin exposure variables and 30-day mortality, microbiologic failure, and recurrence are shown in Table 2 . Overall, the findings between the CARTderived vancomycin exposure variables and 30-day mortality, microbiologic failure, and recurrence were generally consistent with the exposure-failure analyses.
Results of the Poisson regression analyses for failure and 30-day mortality are displayed in Table 3 . Baseline covariates associated with failure or 30-day mortality at a P value <.2 were considered as potential confounders at model entry in each set of multivariate analyses (Table 4) . Overall, no notable relationships were observed between the CART-derived C min / MIC exposure variables and failure. In contrast, all adjusted relative risks were <1 for the CART-derived AUC/MIC exposure variables. Similar to the bivariate analyses, the risk of failure was 50% lower in those with exposures in excess of the CART-derived AUC/MIC thresholds relative to those below the AUC/MIC ratio breakpoints. The results from the "30-day mortality" Poisson regression analyses were largely similar to the "failure" Poisson regression analyses. All CART-derived AUC/MIC exposures and C min0−24h /MIC ETEST ≥4.4 were associated with a lower risk of 30-day mortality.
DISCUSSION
Using a validated method to determine exposure profiles among patients with "trough-only" PK sampling [22] , the analyses presented here suggest that AUC/MIC is the pharmacodynamic index most closely linked to outcomes for vancomycin. Achievement of exposure values in excess of the CART-derived AUC/MIC breakpoints were associated with failure rates of 20%-25%, consistent with the near-maximal effect expected for patients with MRSA BSIs [18, 24, 42] . In contrast, failure to achieve the CART-derived AUC/MIC exposure thresholds was associated with failure rates >40%. In the multivariate analyses (Table 3) , all RRs were approximately 0.5, indicating that achievement of CART-derived AUC/MIC exposure thresholds was associated with a 2-fold decrease in failure. Similarly, achievement of the CART-derived AUC/MIC exposures was associated with a 2-2.5 fold reduction in 30-day mortality. Collectively, these findings establish the critical importance of the daily AUC/MIC ratios during the first 2 days of vancomycin therapy. Unfortunately, this study lacked power to discriminate between AUC/MIC BMD and AUC/MIC ETEST and day 1 and 2 exposures. All CART-derived AUC/MIC exposure variables across both time intervals (day 1 and day 2) were found to be similarly associated with outcomes. Not surprisingly, the CART-derived exposure AUC/MIC BMD and AUC/MIC ETEST [22, 43, 44] . Alternatively, vancomycin AUCs can be calculated using formulas based on the collection of a few timed measurements [10] . As with all observational studies, these findings should be interpreted cautiously and need to be validated in a multicenter randomized trial before adoption into practice. However, it is important to note that the current "AUC/MIC ratio >400" PK/PD target for vancomycin is based on studies [5, 7, 8] with designs similar to this one. Two additional findings bear mention here. First, no noteworthy relationships between C min /MIC and outcomes were observed in this study. Although expert guidelines recommend trough monitoring [1, 2] , this was not an unexpected finding from an exposure-response perspective. Troughs are a single point estimate of the concentration-time profile at the end of the dosing interval. Whereas a trough ensures the achievement of a minimum cumulative exposure, a wide range of concentrationtime profiles can result in a given C min [10] . Because cumulative exposure profiles associated with a given trough value are highly variable [10] , it is not surprising that C min was found to be uninformative and nondiscriminatory. These findings further support the notion that AUC monitoring should be incorporated into clinical practice, as it has been identified as the key pharmacodynamic index for vancomycin across a growing number of in vitro, animal model, and clinical studies [1] [2] [3] [4] [5] [6] [7] [8] 45] .
Second, whereas the observed vs predicted plots for the Bayesian approach showed slopes and intercepts very close to the ideal values of 1.0 and 0.0, respectively, the formula-based approach did not fit the data well and only explained 35% of the variance. The poor fit associated with the Cockcroft-Gault formula best approach does not come as a surprise. This finding was consistent with older gentamicin PK data, which demonstrated that CrCL-based estimation formulas did not accurately predict the observed concentration-time profiles of gentamicin, an antibiotic that is predominately cleared by the kidneys, similar to vancomycin [9] . This finding further supports the notion that individualized estimates of exposure profiles based on measured vancomycin concentrations are required when evaluating vancomycin exposure-response relationships in clinical practice. Interestingly, the formula-based approach underestimated exposure profiles by approximately 40%-50% (overestimated clearance by 40%-50%). If one considers that AUC = dose/ clearance, our daily AUC target of 550-600 aligns closely with previous evaluations [5, 7, 8] that noted the critical AUC/MIC target to be approximately 400.
Several caveats should be noted when interpreting these findings. First, this was a study of adult, non-neutropenic, nondialysis patients. It is unknown if the observed findings are applicable to other populations. Second, only a limited number of isolates had MIC BMD >1 mg/L. The current paradigm in PK/PD is that a doubling of exposure is required with each log 2 increase in MIC values. Before we definitively recommend a daily AUC of 1300 for an MIC BMD of 2 mg/L, additional research is needed. If future studies indicate the pharmacodynamic target is consistent with the AUC/MIC BMD targets observed in this study when the MIC BMD is 2 mg/L, it will be difficult to use vancomycin in these instances as the vancomycin AUC needed for effect will be associated with nephrotoxicity rates >30% [21] .
We did not attempt to determine if 30-day mortality was attributable to the MRSA BSI. Rather than basing microbiological failure on persistent signs and symptoms of infection, treatment was considered a microbiological failure only if the duration of bacteremia was ≥7 days, as proposed by a number of authors [18, 27, 38] . We believe these aforementioned definitions allow for an objective assessment of the endpoints and minimize any subjective biases that may result from assessing and interpreting retrospective clinical data. Another consideration in the evaluation of MRSA bloodstream infection studies is the adequacy of source control. In situations when source control was warranted, there was an attempt to remove the catheter/debride the wound in almost all cases. Among patients who experienced a failure, there was a documented intervention in the medical record to "control the source" in >95% of cases. The frequency of source control attempts were not different between CARTderived exposure groups.
In conclusion, our findings suggest that that AUC/MIC, not C min /MIC, is the pharmacodynamic index most closely linked to outcomes for patients with MRSA BSIs. Clinicians should conservatively target AUC values needed to provide adequate exposure against the common MIC values observed in their institution, given that MICs are largely unknown until therapy day 3. Further research is still needed among patients with MRSA BSIs with vancomycin MIC BMD >1 mg/L. As this was a retrospective observational study, these findings need to be validated in a multicenter vancomycin AUC dose-optimized randomized outcomes trial before they can be incorporated into clinical practice.
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